CN106999467A - 治疗认知减退的方法 - Google Patents

治疗认知减退的方法 Download PDF

Info

Publication number
CN106999467A
CN106999467A CN201580066475.3A CN201580066475A CN106999467A CN 106999467 A CN106999467 A CN 106999467A CN 201580066475 A CN201580066475 A CN 201580066475A CN 106999467 A CN106999467 A CN 106999467A
Authority
CN
China
Prior art keywords
thc
patient
administered
age
tetrahydrocannabinol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580066475.3A
Other languages
English (en)
Chinese (zh)
Inventor
Y·萨恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CN106999467A publication Critical patent/CN106999467A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580066475.3A 2014-11-03 2015-11-02 治疗认知减退的方法 Pending CN106999467A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074134P 2014-11-03 2014-11-03
US62/074,134 2014-11-03
PCT/IB2015/058453 WO2016071819A1 (en) 2014-11-03 2015-11-02 Methods for treatment of cognitive decline

Publications (1)

Publication Number Publication Date
CN106999467A true CN106999467A (zh) 2017-08-01

Family

ID=55908668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580066475.3A Pending CN106999467A (zh) 2014-11-03 2015-11-02 治疗认知减退的方法

Country Status (7)

Country Link
US (1) US10660872B2 (https=)
EP (1) EP3215148B1 (https=)
JP (1) JP6676062B2 (https=)
CN (1) CN106999467A (https=)
AU (2) AU2015341458B2 (https=)
CA (1) CA2966710A1 (https=)
WO (1) WO2016071819A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11065225B1 (en) * 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
US11446276B2 (en) 2015-07-30 2022-09-20 University Of South Florida Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease
GB2549277B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
BR112020019768A2 (pt) 2018-03-30 2021-01-26 India Globalization Capital, Inc. método e composição para o tratamento de distúrbios do sistema nervoso central (snc)
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US7648696B2 (en) 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
WO2012068516A2 (en) 2010-11-18 2012-05-24 Pier Pharmaceuticals Low dose cannabinoid medicaments
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Y SARNE等: "The Dual Neuroprotective-Neurotoxic Profile of Cannabinoid Drugs", 《BRITISH JOURNAL OF PHARMACOLOGY》 *

Also Published As

Publication number Publication date
JP6676062B2 (ja) 2020-04-08
WO2016071819A1 (en) 2016-05-12
US20170333387A1 (en) 2017-11-23
AU2015341458B2 (en) 2020-08-13
EP3215148A4 (en) 2018-06-13
EP3215148A1 (en) 2017-09-13
AU2020267285A1 (en) 2020-12-10
EP3215148B1 (en) 2022-04-13
JP2017533276A (ja) 2017-11-09
CA2966710A1 (en) 2016-05-12
US10660872B2 (en) 2020-05-26
AU2015341458A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
US10660872B2 (en) Methods for treatment of cognitive decline
EP2037902B1 (en) Cannabinoids for use in the treatment of neuropathic pain
JP7210564B2 (ja) カンナビジオールによる脆弱ｘ症候群の処置
GB2432312A (en) Pharmaceutical compositions for the treatment of pain
JP2021525709A (ja) 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物
CN107951869A (zh) 含有大麻二酚的药物制剂及其应用
MXPA06006685A (es) Uso de gaboxadol para tratar el insomnio.
CN104906501A (zh) 治疗银屑病的中药组分组合物
CN105726557A (zh) 异长春花苷内酰胺在制备治疗肠应激综合征的药物中的应用
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
TWI599371B (zh) 醫藥組合物用於製備治療檳榔使用失調之藥物上的用途
JP2004083553A (ja) ギンコライド−ａを含有する抗不安剤
Miculas et al. Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells 2023, 12, 131
CN108245510B (zh) 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
JP6738797B2 (ja) レット症候群治療薬
JP5978471B2 (ja) 耳鳴患者の治療用の薬剤
WO2026052068A1 (zh) 药物组合物的用途
WO2018029685A1 (en) Compositions and methods for treating a fear memory

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170801